An active immunotherapy maintenance treatment for acute myeloid leukemia (AML) and ovarian cancer, designed to stimulate the immune system against residual cancer cells.

An intratumoral immune primer consisting of pro-inflammatory dendritic cells administered directly into tumors to induce local inflammation and anti-tumor immune responses.